Companies › Boryung Pharmaceutical
11 active drug programs in 73 registered trials: 22 Phase 3, 22 Phase 2, 19 Phase 1, 10 Phase 4; Cardiovascular, Oncology, Metabolic and endocrine, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Dapagliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 4 | Type 2 Diabetes; Diabetes Mellitus; Diabete Mellitus | – |
| BR1019A | – | Phase 3 | Essential Hypertension | Dec 2026 |
| BR1019A-1 | – | Phase 3 | Essential Hypertension | Dec 2026 |
| BR1019B | – | Phase 3 | Essential Hypertension | Dec 2026 |
| BR1019C | – | Phase 3 | Essential Hypertension | Dec 2026 |
| Olanzapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; D2-like dopamine receptor antagonist | HTR2A, HTR2C, DRD2, DRD3, DRD4 | Phase 2 | Schizophrenia; Schizophrenia and Related Disorders; Chemotherapy Induced Nausea and Vomiting; Oncology Patients Receiving Chemotherapy … | May 2027 |
| BR2021 | – | Phase 1 | Metastatic Adenocarcinoma of the Pancreas | – |
| BR2021-1 | – | Phase 1 | Metastatic Adenocarcinoma of the Pancreas | – |
| Metformin Hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor; Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor | MT-ND6, NDUFA10, NDUFS8, MT-ND4L, NDUFA6 | Phase 1 | Diabetes Mellitus; Diabete Mellitus; Depression; Polycystic Ovary Syndrome … | – |
| Olaparib (BR2022) PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 1 | Ovarian Cancer | – |
| Pioglitazone Peroxisome proliferator-activated receptor gamma agonist | PPARG | Phase 1 | Diabetes Mellitus; Diabete Mellitus; Infertility Treatment; Type 2 Diabetes … | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05919147 | Pioglitazone | Phase 2 | Lung Cancer | Oncology | Jun 2025 |
| NCT04576104 | Metformin Hydrochloride | Phase 2 | Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia | Oncology | Aug 2025 |
| NCT06867497 | BR2021 | Phase 1 | Metastatic Adenocarcinoma of the Pancreas | Oncology | Oct 2025 |
| NCT06867497 | BR2021-1 | Phase 1 | Metastatic Adenocarcinoma of the Pancreas | Oncology | Oct 2025 |
| NCT06850454 | Olanzapine | Phase 3 | Chemotherapy Induced Nausea and Vomiting | Other | Jan 2026 |
| NCT07069335 | Olaparib (BR2022) | Phase 1 | Ovarian Cancer | Oncology | May 2026 |
| NCT07462065 | Pioglitazone | Phase 4 | Infertility Treatment | Other | Jun 2026 |
| NCT07083388 | Dapagliflozin | Phase 1 | Diabetes Mellitus | Metabolic and endocrine | Jul 2026 |
| NCT07083388 | Dapagliflozin | Phase 1 | Diabetes Mellitus | Metabolic and endocrine | Jul 2026 |
| NCT07083388 | Pioglitazone | Phase 1 | Diabetes Mellitus | Metabolic and endocrine | Jul 2026 |
| NCT07083388 | Metformin Hydrochloride | Phase 1 | Diabetes Mellitus | Metabolic and endocrine | Jul 2026 |
| NCT07083401 | Dapagliflozin | Phase 1 | Diabete Mellitus | Metabolic and endocrine | Jul 2026 |
| NCT07083401 | Dapagliflozin | Phase 1 | Diabete Mellitus | Metabolic and endocrine | Jul 2026 |
| NCT07083401 | Pioglitazone | Phase 1 | Diabete Mellitus | Metabolic and endocrine | Jul 2026 |
| NCT07083401 | Metformin Hydrochloride | Phase 1 | Diabete Mellitus | Metabolic and endocrine | Jul 2026 |
| NCT06972732 | Dapagliflozin | Phase 4 | Type 2 Diabetes | Metabolic and endocrine | Oct 2026 |
| NCT01905046 | Metformin Hydrochloride | Phase 3 | Breast Atypical Ductal Hyperplasia | Oncology | Nov 2026 |
| NCT06554613 | Olanzapine | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT02336087 | Metformin Hydrochloride | Phase 1 | Pancreatic Adenocarcinoma | Oncology | Dec 2026 |
| NCT06220773 | BR1019A | Phase 3 | Essential Hypertension | Cardiovascular | Dec 2026 |
| NCT06220773 | BR1019B | Phase 3 | Essential Hypertension | Cardiovascular | Dec 2026 |
| NCT06220773 | BR1019C | Phase 3 | Essential Hypertension | Cardiovascular | Dec 2026 |
| NCT06220773 | BR1019A-1 | Phase 3 | Essential Hypertension | Cardiovascular | Dec 2026 |
| NCT05013255 | Pioglitazone | Phase 2 | Breast Cancer | Oncology | Dec 2026 |
| NCT06707012 | Metformin Hydrochloride | Phase 4 | Depression | Psychiatry | Dec 2026 |
| NCT05237960 | Metformin Hydrochloride | Phase 2 | Erythroplakia | Oncology | Dec 2026 |
| NCT05023967 | Metformin Hydrochloride | Phase 2 | Anatomic Stage I Breast Cancer AJCC v8 | Oncology | Dec 2026 |
| NCT02581137 | Metformin Hydrochloride | Phase 2 | Erythroplakia | Oncology | Dec 2026 |
| NCT07633236 | Olanzapine | Phase 3 | Oncology Patients Receiving Chemotherapy | Oncology | Dec 2026 |
| NCT05680805 | Metformin Hydrochloride | Phase 4 | Polycystic Ovary Syndrome | Metabolic and endocrine | Dec 2026 |
| NCT04939090 | Olanzapine | Phase 3 | Advanced Malignant Solid Neoplasm | Oncology | Dec 2026 |
| NCT06989723 | Pioglitazone | Phase 4 | Type 2 Diabetes | Metabolic and endocrine | Dec 2026 |
| NCT04931017 | Metformin Hydrochloride | Phase 2 | Lung Carcinoma | Oncology | Dec 2026 |
| NCT03109288 | Pioglitazone | Phase 1 | Multiple Sclerosis | Neurology | Jan 2027 |
| NCT06611501 | Metformin Hydrochloride | Phase 2 | Pelvic Pain | Genitourinary | Jan 2027 |
| NCT06314906 | Olanzapine | Phase 3 | Electroacupuncture | Oncology | Jan 2027 |
| NCT03781115 | Olanzapine | Phase 1 | Schizophrenia | Psychiatry | Feb 2027 |
| NCT05893225 | Metformin Hydrochloride | Phase 2 | Multiple Sclerosis | Neurology | Feb 2027 |
| NCT06338683 | Olanzapine | Phase 3 | Advanced Cancer | Oncology | Mar 2027 |
| NCT05305287 | Pioglitazone | Phase 4 | Non-Alcoholic Fatty Liver Disease | Metabolic and endocrine | Mar 2027 |
| NCT06821945 | Olanzapine | Phase 2 | Schizophrenia | Psychiatry | May 2027 |
| NCT07056699 | Pioglitazone | Phase 3 | Type1diabetes | Metabolic and endocrine | Jun 2027 |
| NCT07053319 | Pioglitazone | Phase 1 | Type 2 Diabetes | Metabolic and endocrine | Jun 2027 |
| NCT07455955 | Olanzapine | Phase 2 | Breast Cancer | Oncology | Jun 2027 |
| NCT05705492 | Olanzapine | Phase 2 | Advanced Malignant Solid Neoplasm | Oncology | Jun 2027 |
| NCT05445791 | Metformin Hydrochloride | Phase 3 | Non Small Cell Lung Cancer | Oncology | Jul 2027 |
| NCT06446531 | Pioglitazone | Phase 1 | Pre-Diabetes | Cardiovascular | Jul 2027 |
| NCT04758000 | Metformin Hydrochloride | Phase 2 | Osteosarcoma | Oncology | Jul 2027 |
| NCT04501406 | Pioglitazone | Phase 2 | Type 2 Diabetes Mellitus (T2DM) | Metabolic and endocrine | Aug 2027 |
| NCT07413809 | Olanzapine | Phase 3 | Multiple Myeloma | Oncology | Sep 2027 |
| NCT05895838 | Olanzapine | Phase 3 | Out-Of-Hospital Cardiac Arrest | Cardiovascular | Sep 2027 |
| NCT07387900 | Metformin Hydrochloride | Phase 2 | Oral Leukoplakia | Oncology | Sep 2027 |
| NCT04478838 | Olanzapine | Phase 4 | Schizophrenia and Related Disorders | Psychiatry | Sep 2027 |
| NCT07699276 | Olanzapine | Phase 2 | Cancer (Solid Tumors) | Oncology | Oct 2027 |
| NCT06588413 | Olanzapine | Phase 3 | Multiple Myeloma | Oncology | Oct 2027 |
| NCT06200181 | Olanzapine | Phase 3 | Misuse, Opioid | Psychiatry | Nov 2027 |
| NCT05230758 | Metformin Hydrochloride | Phase 3 | Medulloblastoma, Childhood | Oncology | Nov 2027 |
| NCT06657209 | Pioglitazone | Phase 4 | Diabetes Mellitus, Type 2 | Metabolic and endocrine | Dec 2027 |
| NCT02889003 | Pioglitazone | Phase 2 | Chronic Myeloid Leukemia (CML) | Oncology | Dec 2027 |
| NCT02767063 | Pioglitazone | Phase 1 | Leukemia, Myeloid, Chronic-Phase | Oncology | Dec 2027 |
The 60 nearest readouts of 73 trials; the rest in the app.
Tasly Pharmaceuticals JW Pharmaceutical Yuhan Sinotau Pharmaceutical Group Shenzhen Salubris Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.